BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 10:30 am Sale | 2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -3,360,941 (Position Closed) | Filing |
| 2023-03-16 4:48 pm Purchase | 2023-03-06 | 13G | Aclaris Therapeutics, Inc. ACRS | BIOTECHNOLOGY VALUE FUND L P | 3,360,941 5.000% | 84,398 (+2.58%) | Filing |
| 2023-02-14 11:40 am Sale | 2022-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | BIOTECHNOLOGY VALUE FUND L P | 3,276,543 4.900% | -591,500 (-15.29%) | Filing |
| 2022-01-24 5:23 pm Purchase | 2022-01-13 | 13G | Aclaris Therapeutics, Inc. ACRS | BIOTECHNOLOGY VALUE FUND L P | 3,868,043 6.300% | 3,868,043 (New Position) | Filing |